Evidence map›Paper›PMID 33442116›Full record

ArticleJournal of the ASEAN Federation of Endocrine Societies2018

The Multicenter, Open-Label, Observational LEAD-Ph Study: Real-World Safety and Effectiveness of Liraglutide in Filipino Participants with Type 2 Diabetes.

Cecilia Jimeno, Sjoberg Kho, Grace Ko de Los Santos, Neslie Buena-Bobis, Michael Villa

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the ASEAN Federation of Endocrine Societies, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01345734. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01345734 completed

Liraglutide Effectiveness and Safety Data From Routine Clinical Practice in Philippines Study. A Multicentre, Open Label, Observational, Non-interventional Study to Evaluate the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes Mellitus in Philippines

Ran2011Enrolled1,056Registered outcomes5Posted comparisons0ConditionsDiabetes, Diabetes Mellitus, Type 2Armsliraglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Cecilia JimenoDepartment of Pharmacology and Toxicology, College of Medicine; Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, Philippine General Hospital, University of the Philippines.
Sjoberg KhoSection of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Santo Tomas Hospital, Philippines.
Grace Ko de Los SantosDepartment of Medicine, Far Eastern University - Nicanor Reyes Medical Foundation, Philippines.
Neslie Buena-BobisNovo Nordisk Pharmaceuticals (Phils) Bonifacio Global City, Taguig, Philippines.
Michael VillaCenter for Diabetes, Thyroid and Endocrine Disorders, St. Luke's Medical Center, Global City, Taguig, Philippines.
Diabetes Australia · AUFar Eastern University · THSt. Luke's Medical Center · PHUniversity of Santo Tomas Hospital · PH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAssess safety and effectiveness of liraglutide among Filipino participants with type 2 diabetes (T2D) in routine clinical practice. METHODOLOGY: A 26-week, prospective, multicenter, open-label, observational study was conducted in adults with T2D prescribed liraglutide (1.2 mg or 1.8 mg) in routine clinical practice in the Philippines. Primary endpoint: incidence rate and type of serious adverse drug reactions (SADRs). Secondary endpoints included other aspects of safety, and effectiveness.

resultsParticipants (n=1056) had a mean (standard deviation) age of 53.2 (12.0) years, and glycated hemoglobin (HbA

conclusionDuring routine clinical use of liraglutide for T2D in the Philippines, no new safety concerns were identified and blood glucose was lowered effectively.

Indexed as

glucagon-like peptidesliraglutideobservational studyPhilippinessafetytype 2 diabetes mellitus

Identifiers

PMID33442116
PMCPMC7784181
OpenAlexW2895214280

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.